While engraftment is the desired end point of hematopoietic stem cell transplantation
(HSCT), the phase of neutrophil recovery can be complicated by two acute entities termed …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) entails substantial
nonrelapse mortality (NRM) and brings acute graft-versus-host disease (GVHD) as the main …

Setting: The study was conducted at bone marrow transplantation unit, 57357 Cancer
Hospital in Cairo, Egypt Sample size: The study sample was a convenience sample …

The overarching aim of this work was to investigate the effects of hypoxic culture on
mesenchymal stromal cell (MSC) immunomodulation and biodistribution in-vitro and in-vivo …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most common T cell
therapy procedure, yet little is known about how best to harness the graft-versus-tumor …

0003 Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for
both benign and malignant lymphohematopoietic diseases and is being explored for a …

La réaction du greffon contre l'hôte (GvH) est responsable d'un grand taux de morbidité et
de mortalité chez les patients recevant des greffes de cellules souches (GCSH) …

The limiting factor to the broad use of bone marrow transplantation (BMT) to cure
hematopoietic malignancy is graft verses host disease (GVHD). GVHD is caused by mature …

Our ability to give a patient an accurate risk assessment for GvHD is improving. Likewise,
novel approaches to GvHD prevention and treatment are allowing for more intensive …

Minor histocompatibility antigens (MiHA) play an important role in both graft-versus-tumor
effects and graft-versus-host disease (GvHD) after allogeneic stem cell transplantation. We …